BACKGROUND: Although line-probe assays (LPAs) are promising, little research has been conducted to elucidate the true nature of indeterminate LPA results or assess the ability of these assays to perform on a wide range of clinical samples. OBJECTIVE: To evaluate the performance of the commercially available GenoType(®) MTBDRplus LPA against conventional BACTEC™ MGIT™ 960 culture and drug susceptibility testing (DST) among 308 pulmonary tuberculosis (PTB) and 32 extra-pulmonary TB samples. RESULTS: Invalid LPA results (defined as those with a missing Mycobacterium tuberculosis identification band) were obtained for 18 PTB samples, which were excluded from further analysis. The sensitivity and specificity of the MTBDRplus assay for multidrug-resistant TB, based upon the results obtained for the remaining 322 samples, was respectively 95.2% and 95.1%. Of 290 PTB samples, 40 (13.7%) were indeterminate on LPA (defined as the absence of both wild-type and corresponding mutation bands) for isoniazid (INH) and/or rifampicin (RMP), and were further evaluated by pyrosequencing (PSQ). Contrary to standard LPA interpretation, INH and RMP susceptibility were confirmed by both DST and PSQ in respectively 7.5% (3/40) and 27.5% (11/40) of indeterminate samples. CONCLUSION: PSQ was found to be a valuable and rapid technique to resolve discrepancies in LPA test results that were not interpretable.
BACKGROUND: Although line-probe assays (LPAs) are promising, little research has been conducted to elucidate the true nature of indeterminate LPA results or assess the ability of these assays to perform on a wide range of clinical samples. OBJECTIVE: To evaluate the performance of the commercially available GenoType(®) MTBDRplus LPA against conventional BACTEC™ MGIT™ 960 culture and drug susceptibility testing (DST) among 308 pulmonary tuberculosis (PTB) and 32 extra-pulmonary TB samples. RESULTS: Invalid LPA results (defined as those with a missing Mycobacterium tuberculosis identification band) were obtained for 18 PTB samples, which were excluded from further analysis. The sensitivity and specificity of the MTBDRplus assay for multidrug-resistant TB, based upon the results obtained for the remaining 322 samples, was respectively 95.2% and 95.1%. Of 290 PTB samples, 40 (13.7%) were indeterminate on LPA (defined as the absence of both wild-type and corresponding mutation bands) for isoniazid (INH) and/or rifampicin (RMP), and were further evaluated by pyrosequencing (PSQ). Contrary to standard LPA interpretation, INH and RMP susceptibility were confirmed by both DST and PSQ in respectively 7.5% (3/40) and 27.5% (11/40) of indeterminate samples. CONCLUSION: PSQ was found to be a valuable and rapid technique to resolve discrepancies in LPA test results that were not interpretable.
Authors: V V Nikolayevskyy; T J Brown; Y I Bazhora; A A Asmolov; Y M Balabanova; F A Drobniewski Journal: Clin Microbiol Infect Date: 2007-02 Impact factor: 8.067
Authors: Johanna Mäkinen; Harri J Marttila; Merja Marjamäki; Matti K Viljanen; Hanna Soini Journal: J Clin Microbiol Date: 2006-02 Impact factor: 5.948
Authors: Lulette Tricia C Bravo; Marion J Tuohy; Concepcion Ang; Raul V Destura; Myrna Mendoza; Gary W Procop; Steven M Gordon; Geraldine S Hall; Nabin K Shrestha Journal: J Clin Microbiol Date: 2009-10-21 Impact factor: 5.948
Authors: R Vijdea; M Stegger; A Sosnovskaja; A B Andersen; V Ø Thomsen; D Bang Journal: Eur J Clin Microbiol Infect Dis Date: 2008-06-05 Impact factor: 3.267
Authors: M L Pérez Del Molino; G Barbeito-Castiñeiras; B Mejuto; P Alonso; A Fernández; G González-Mediero Journal: Eur J Clin Microbiol Infect Dis Date: 2016-09-01 Impact factor: 3.267
Authors: K Sharma; A Gupta; M Sharma; A Sharma; R Singh; K Aggarwal; R Bansal; A Thakur; S Prakash; V Gupta Journal: Eye (Lond) Date: 2017-10-20 Impact factor: 3.775
Authors: Adebisi Ajileye; Nataly Alvarez; Matthias Merker; Timothy M Walker; Suriya Akter; Kerstin Brown; Danesh Moradigaravand; Thomas Schön; Sönke Andres; Viola Schleusener; Shaheed V Omar; Francesc Coll; Hairong Huang; Roland Diel; Nazir Ismail; Julian Parkhill; Bouke C de Jong; Tim E A Peto; Derrick W Crook; Stefan Niemann; Jaime Robledo; E Grace Smith; Sharon J Peacock; Claudio U Köser Journal: Antimicrob Agents Chemother Date: 2017-03-24 Impact factor: 5.191